Integer (NYSE:ITGR) Releases FY24 Earnings Guidance

Integer (NYSE:ITGR) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $5.01-5.43 for the period, compared to the consensus EPS estimate of $5.31. The company issued revenue guidance of 1.74-1.77 billion, compared to the consensus revenue estimate of $1.76 billion. Integer also updated its FY 2024 guidance to 5.010-5.430 EPS.

Integer Stock Performance

Shares of ITGR stock traded down $1.56 during trading hours on Friday, reaching $109.59. 604,251 shares of the company’s stock were exchanged, compared to its average volume of 342,875. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71. The company’s 50 day moving average is $112.91 and its two-hundred day moving average is $99.57. The company has a market cap of $3.67 billion, a P/E ratio of 40.36, a price-to-earnings-growth ratio of 1.71 and a beta of 1.10. Integer has a 1 year low of $69.40 and a 1 year high of $123.99.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. The firm had revenue of $414.80 million for the quarter, compared to analyst estimates of $412.78 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. Integer’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.87 earnings per share. Equities research analysts anticipate that Integer will post 5.31 EPS for the current fiscal year.

Analyst Ratings Changes

ITGR has been the topic of several research analyst reports. Benchmark reissued a buy rating and set a $130.00 price target on shares of Integer in a research note on Friday. CL King assumed coverage on Integer in a research note on Thursday, March 14th. They set a buy rating and a $137.00 price target for the company. Bank of America raised shares of Integer from a neutral rating to a buy rating and increased their price objective for the company from $105.00 to $135.00 in a research note on Monday, April 15th. Finally, KeyCorp upped their price target on shares of Integer from $123.00 to $139.00 and gave the company an overweight rating in a report on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $120.50.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.